Advanced in Primitive Neuroectodermal Tumor (PNET)

Dr. Michael Glantz

Neurology
Office
30 Hope Dr Ste 1200, 
Hershey, PA 
Advanced in Primitive Neuroectodermal Tumor (PNET)
Office
30 Hope Dr Ste 1200, 
Hershey, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Glantz is a Neurologist in Hershey, Pennsylvania. Dr. Glantz is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Thrombectomy.

His clinical research consists of co-authoring 71 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Neurological Surgery in PA
Hospital Affiliations
North Adams Regional Hospital Corporation
Berkshire Medical Center
Fairview Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 7 Less Insurance Carriers -

Locations

Office
30 Hope Dr Ste 1200, Hershey, PA 17033
Other Locations
Berkshire Internists of BMC
777 North St, Pittsfield, MA 01201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)
An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors
A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
A Biospecimen Collection Study to Evaluate the Pharmacokinetic, Pharmacodynamic, and Resistance Profile to Trametinib and Dabrafenib in BRAF-V600E Mutated Recurrent Gliomas
A Biospecimen Collection Study to Evaluate the Pharmacokinetic, Pharmacodynamic, and Resistance Profile to Trametinib and Dabrafenib in BRAF-V600E Mutated Recurrent Gliomas
Enrollment Status: Terminated
Publish Date: October 06, 2023
Intervention Type: Procedure
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

71 Total Publications

BNIP3-mTOR Signaling Mediates Resistance to MET Inhibition in Glioblastoma.
BNIP3-mTOR Signaling Mediates Resistance to MET Inhibition in Glioblastoma.
Journal: bioRxiv : the preprint server for biology
Published: January 08, 2026
Similar Doctors
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Na Gatson
Neurology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Na Gatson
Neurology

Select Specialty Hospital-Danville

100 N Academy Ave, 
Danville, PA 
 (200.0 miles away)
570-271-6144
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Na Gatson is a Neurologist in Danville, Pennsylvania. Dr. Gatson has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Brain Tumor, Astrocytoma, Glioblastoma, and Glioma.

Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. David Long
Neurology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. David Long
Neurology

BRYN Mawr Rehabilitation Hospital

414 Paoli Pike, 
Malvern, PA 
 (205.2 miles away)
610-649-3943
Languages Spoken:
English

David Long is a Neurologist in Malvern, Pennsylvania. Dr. Long is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), Metastatic Brain Tumor, and Astrocytoma.

Experienced in Primitive Neuroectodermal Tumor (PNET)
Dr. Chad M. Miller
Neurology
Experienced in Primitive Neuroectodermal Tumor (PNET)
Dr. Chad M. Miller
Neurology

Pottstown Hospital

1600 East High Street, 
Pottstown, PA 
 (194.7 miles away)
610-327-7000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

. Dr. Miller is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Stroke, Subarachnoid Hemorrhage, Apoplexy, Transmyocardial Revascularization, and Stent Placement.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Glantz's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile